{
  "snapshot_date": "2026-04-26",
  "source": "synthetic_fda_newsroom",
  "items": [
    {
      "id": "FDA-SYN-2026-0411",
      "headline": "FDA grants priority review for synthetic FXR agonist (synthetic)",
      "category": "regulatory",
      "drugs": ["vonafexor"],
      "date": "2026-04-22"
    },
    {
      "id": "FDA-SYN-2026-0412",
      "headline": "Hepatology AdComm scheduled for FGF21 program (synthetic)",
      "category": "regulatory",
      "drugs": ["pegozafermin"],
      "date": "2026-04-23"
    },
    {
      "id": "FDA-SYN-2026-0413",
      "headline": "Generic pioglitazone label revision finalized (synthetic)",
      "category": "label",
      "drugs": ["pioglitazone"],
      "date": "2026-04-24"
    },
    {
      "id": "FDA-SYN-2026-0414",
      "headline": "Synthetic accelerated approval converted to traditional approval for THR-beta agent (synthetic)",
      "category": "regulatory",
      "drugs": ["resmetirom"],
      "date": "2026-04-26"
    },
    {
      "id": "FDA-SYN-2026-0415",
      "headline": "Safety signal review opened for an investigational FASN inhibitor (synthetic)",
      "category": "safety",
      "drugs": ["denifanstat"],
      "date": "2026-04-26"
    }
  ]
}